Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLID.L Regulatory News (LID)

  • There is currently no data for LID

US distribution agreement

29 Jul 2008 07:00

RNS Number : 0596A
LiDCO Group Plc
29 July 2008
 



Press Release 

29 July 2008

LiDCO Group Plc

("LiDCO" or the "Company")

US distribution agreement

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to announce it has signed an exclusive distribution agreement with US speciality distributor KOL Bio Medical Instruments (KOL) for the sale of the LIDCOrapid Monitor in certain territories in the US. 

It is estimated that the American market for minimally invasive hemodynamic monitoring market for high risk surgery is currently valued at US$238m. 

KOL is a 37 year old speciality distributor of medical technology with extensive experience of selling hemodynamic monitoring equipment. The company has a 15 strong specialist sales team and currently supplies to 21 states on the Eastern side of the USA. LiDCO also distributes to other parts of the USA via its own sales force of 5 people. This combined and significantly enlarged sales force gives LiDCO access to more than 40% of US market. LiDCO expects there will be additional distributor appointments for the states not currently covered by either sales force. 

Timothy McInerney CEO of KOL (www.kolbio.com) said: "We have been very impressed with the LiDCOrapid Monitor. We have seen an increased demand from the US healthcare market for an easy to use, minimally invasive, precise hemodynamic monitoring product for surgery. The release of the LiDCOrapid is very timely, since the continuing downward trend in the use of thermodilution catheters has left many US physicians without an effective way to monitor and manage the key variables associated with optimal hemodynamic performance. The minimally invasive LiDCOrapid provides the perfect dashboard for assessment and control of these critical parameters in medium to high risk patients. It appears to be the perfect solution at a perfect time."

Dr Terry O'Brien, CEO of LiDCO, commented: "I am delighted to be working with KOL. The company has an eminent reputation and for some time has been one of the leading medical distributors in the US. Together with KOL we have seen strong interest for the LIDCOrapid Monitor in the US, since we launched in April this year. I anticipate that this partnership will be very productive for both companies." 

- ENDS - 

For more information please contact:

LiDCO Group Plc

Terry O'Brien - Chief Executive

John Rowland - Company Secretary

Tel: +44 (0)20 7749 1500

www.lidco.com 

Panmure Gordon and Co

Edward Farmer/ Katherine Roe

+44 (0)20 7459 3600

www.panmure.com 

Media enquiries

Abchurch Communications

Heather Salmond / Stephanie Cuthbert / Simone Alves

+44 (0)20 7398 7728

simone.alves@abchurch-group.com 

www.abchurch-group.com 

About LiDCO Group Plc

LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's manufacturing facility is in Hoxton, London and its current products are:

* LiDCOplus and PulseCO monitors: these computer-based platforms are used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid volume (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care. The monitor features many clinical benefits. These enable acute care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being during and after surgery. 

LiDCOrapid provides:

Early and rapid warning of change

Clear indication of therapeutic route: fluid or drug

Quantification of hemodynamic response, particularly stroke volume

Permits more effective delivery of fluids - the right amount at the right time

Advanced hemodynamic care advantages:

Contributes to reduced morbidity and complications

Reduces length of stay

Reduces overall cost of care

* LiDCO disposables: used in conjunction with the LiDCOplus Monitor for accurate measurement of cardiac output in a minimally invasive manner

LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase

* LiDCOlive: a software product in development for the remote display of hemodynamic monitoring parameters derived through use of the LiDCOplus or LiDCOrapid monitors

LiDCO Distribution Network:

The Company sells direct in the UK, direct and through partners in the USA, and elsewhere through a worldwide network of speciality critical care and anesthesia distributors.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCRPMRTMMMTBMP
Date   Source Headline
12th Feb 20207:00 amRNSHolding(s) in Company
6th Feb 20207:00 amRNSGrowth & Innovation Forum 2020
3rd Feb 20207:00 amRNSBlock Listing Review
18th Nov 20199:32 amRNSDirector/PDMR Shareholding
7th Nov 201910:30 amRNSLiDCO to present at Mello London, 2019
5th Nov 20197:00 amRNSLatest monitor launched in China
16th Oct 20197:00 amRNSDirector/PDMR Shareholding
15th Oct 20197:00 amRNSHalf-year Report
12th Sep 20197:00 amRNSCapital Markets Day & technology agreement
20th Aug 20197:00 amRNSCapital Markets Day
20th Aug 20197:00 amRNSTrading update & Notice of results
15th Aug 20197:00 amRNSAppointment of Non-Executive Director
1st Aug 20197:00 amRNSBlock Listing Review
16th Jul 20197:00 amRNSRegulatory approval in China
16th May 201910:30 amRNSResult of AGM
16th May 20197:00 amRNSAGM Statement
23rd Apr 20197:00 amRNSPosting of Annual Report & Accounts &Notice of AGM
17th Apr 20197:00 amRNSRegulatory approval in South Korea
16th Apr 20197:00 amRNSAward of share options/director dealing
2nd Apr 20197:00 amRNSDirector/PDMR Shareholding
1st Apr 20195:48 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSDirector/PDMR Shareholding
27th Mar 20197:00 amRNSDirector/PDMR Shareholding
26th Mar 20197:00 amRNSFinal Results
12th Mar 20197:00 amRNSMaster distribution agreement for Latin America
8th Mar 20197:00 amRNSHUP progress update
5th Mar 20197:00 amRNSDirectorate Change
20th Feb 20195:00 pmRNSHolding(s) in Company
20th Feb 20197:00 amRNSPre-Close Trading Update and Notice of Results
1st Feb 20197:00 amRNSBlock Listing Review
17th Dec 20187:00 amRNSTrading update and notice of results
12th Oct 201811:20 amRNSHolding(s) in Company
9th Oct 20187:01 amRNSHalf-year Report
9th Oct 20187:00 amRNSUK distribution agreement with Shenzhen Antmed
24th Sep 20187:00 amRNSDirectorate Change
20th Aug 20182:58 pmRNSHolding(s) in Company
20th Aug 20187:00 amRNSTrading update & Notice of results
1st Aug 20188:41 amRNSBlock listing Review
19th Jul 20187:00 amRNSUK distribution agreement with Maicuff Technology
29th Jun 20187:11 amRNSAward of share options/director dealing
17th May 201810:36 amRNSResult of AGM
17th May 20187:00 amRNSAGM Statement
16th May 20187:00 amRNSCapital Markets Day & US progress update
24th Apr 20187:00 amRNSCapital Markets Day
24th Apr 20187:00 amRNSPosting of Annual Report & Accounts& Notice of AGM
10th Apr 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSEnd of third party UK Distribution agreement
22nd Feb 20187:00 amRNSAppointment of French distributor
15th Feb 20187:01 amRNSTrading update and notice of results
15th Feb 20187:00 amRNSSignificant US & UK HUP wins

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.